CapitolRadar tracks every publicly disclosed NVO trade by US congress members and corporate insiders: 23 disclosed trades (14 buys, 9 sells) by 6 tracked traders, from 2022-04-20 to 2026-09-10. Updated daily from official filings.
Want a ping when Congress buys NVO? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Novo Nordisk A/S (NVO) — Healthcare · Drug Manufacturers - General, market cap about $169.5B.
CapitolRadar analysis
19 tracked trades, with buys outnumbering sells
Novo Nordisk A/S (NVO), in the Healthcare / Drug Manufacturers - General category, had 19 tracked trades from April 20, 2022 through October 15, 2025. The activity comprised 12 buys and seven sells across four distinct traders. Buys therefore represented the larger side of this limited record, but the sample remains small and spans more than three years.
The specified quarterly data show three buys in 2024 Q2, the highest count among the quarters listed. Both trades in 2025 Q3 were buys, as was the single trade in 2025 Q4. The two trades in 2024 Q4 and two in 2024 Q3 each included one buy, while neither of the two 2024 Q1 trades was a buy. The provided quarterly entries cover 15 trades across eight specified quarters, compared with 19 trades in the full tracked total, so they do not provide a complete quarter-by-quarter breakdown of all activity.
3 named buyers account for all 12 purchases
Michael McCaul recorded five buys, the largest named total, with his latest on October 31, 2024. Ro Khanna recorded four buys, last dated September 8, 2023. Marjorie Taylor Greene recorded three buys, with the latest on October 15, 2025. Together, these named counts equal all 12 tracked buys. The facts identify four distinct traders overall but provide buyer-level details for these three individuals only.
6 other tickers overlap among two buyers each
Two of the NVO buyers also bought each of BAX, DELL, SWK, SPGI, AJG and INTU. These overlaps indicate shared trading activity among a small buyer group, without establishing timing, transaction size or rationale.
Congressional disclosures can be filed up to 45 days after a transaction, so reported activity may appear well after the trade date. Disclosure amounts are generally presented as ranges, making dollar-value figures estimates rather than exact totals; no transaction amounts are provided in these facts. The small number of traders and trades limits broad conclusions.
Analysis written from the tracked record on 2026-09-04; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 4 | 2 | 2 |
| 2025 Q4 | 1 | 1 | 0 |
| 2025 Q3 | 2 | 2 | 0 |
| 2024 Q4 | 2 | 1 | 1 |
| 2024 Q3 | 2 | 1 | 1 |
| 2024 Q2 | 3 | 3 | 0 |
| 2024 Q1 | 2 | 0 | 2 |
| 2023 Q3 | 1 | 1 | 0 |
Who is buying NVO?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Michael McCaul | 5 | 2024-10-31 | — |
| Ro Khanna | 4 | 2023-09-08 | — |
| Marjorie Taylor Greene | 3 | 2025-10-15 | — |
| Scott Mr Franklin | 2 | 2026-08-26 | — |
Disclosed trades in NVO
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-10 | Kevin Hern | sell | $1,001 - $15,000 | — |
| 2026-08-31 | Kevin Hern | sell | $1,001 - $15,000 | — |
| 2026-08-26 | Scott Mr Franklin | buy | $1,001 - $15,000 | — |
| 2026-08-26 | Scott Mr Franklin | buy | $1,001 - $15,000 | — |
| 2025-10-15 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-08-28 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-08-19 | Marjorie Taylor Greene | buy | $15,001 - $50,000 | — |
| 2024-11-19 | Michael McCaul | sell | $50,001 - $100,000 | — |
| 2024-10-31 | Michael McCaul | buy | $15,001 - $50,000 | — |
| 2024-08-26 | Michael McCaul | sell | $1,001 - $15,000 | — |
| 2024-08-09 | Michael McCaul | buy | $15,001 - $50,000 | — |
| 2024-05-29 | Michael McCaul | buy | $15,001 - $50,000 | — |
| 2024-05-28 | Michael McCaul | buy | $15,001 - $50,000 | — |
| 2024-05-06 | Michael McCaul | buy | $15,001 - $50,000 | — |
| 2024-02-09 | Ro Khanna | sell | $50,001 - $100,000 | — |
| 2024-01-19 | Tommy Tuberville | sell | $15,001 - $50,000 | — |
| 2023-09-08 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-03-10 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-02-10 | Ro Khanna | buy | $15,001 - $50,000 | — |
| 2022-12-05 | Ro Khanna | sell | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of NVO disclosed buying in the last six months: DHR (2) · PEP (2) · ACN (2) · TER (2) · MCD (2) · WDAY (2).
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therape…
Frequently asked questions
Which politicians bought NVO most?
Michael McCaul leads with 5 disclosed buys, followed by Ro Khanna.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.